Diagnostic Capability for Colitis Due to Immune-Related Adverse Events (irAEs) with a Focus on Intestinal T Cells

Diagnostic Capability for Colitis Due to Immune-Related Adverse Events (irAEs) with a Focus on Intestinal T Cells - Diagnostic Capability of Intestinal T Cells for irAE Colitis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054198

Enrollment

Registered

2024-04-21

Start date

2024-04-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal disorders associated with irAE

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 18 to under 90 at the time of consent, who are undergoing immune checkpoint inhibitor therapy and are scheduled for endoscopic examination, biopsy, and blood tests.

Exclusion criteria

Exclusion criteria: Women who are pregnant or may be pregnant

Design outcomes

Primary

Measure	Time frame
We isolate lymphocytes from gastrointestinal mucosal biopsy samples of patients undergoing immune checkpoint inhibitor therapy and perform flow cytometry to analyze the composition of lymphocyte fractions. We explore whether the diagnosis of irAE gastrointestinal damage can be based on the proportions of specific T cell subsets.	—

Countries

Japan

Contacts

Public ContactMasaya Iwamuro

Okayama University Hospital Department of Gastroenterology

iwamuromasaya@yahoo.co.jp0862357218

Outcome results